FindTrial
Sign In

Clinical observation of the first-line treatment of diffuse large B cell lymphoma with Thalidomide combined or sequential R-CHOP

Clinical observation of the first-line treatment of diffuse large B cell lymphoma with Thalidomide combined or sequential R-CHOP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016003
Enrollment
Unknown
Registered
2018-05-05
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphoma

Interventions

A:Thalidomide+R-CHOP
B:R-CHOP

Sponsors

The Second Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age = 18 years old; Malignant lymphoma was diagnosed by pathological diagnosis; Can tolerate conventional treatment; ECOG = 2 points; The survival period is more than 3 months; The pregnancy test of female patients was negative; The patient voluntarily participates and signs an informed consent form;

Exclusion criteria

Exclusion criteria: People with a history of thrombosis; Allergic to Thalidomide; Breastfeeding and pregnant women; Are participating in clinical trials of other new drugs;

Design outcomes

Primary

MeasureTime frame
PFS;—

Countries

China

Contacts

Public Contactzhangxian

The Second Affiliated Hospital of Dalian Medical University

17709873632@163.com+86 0411 84671291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026